Compare Prudential Financial Inc (PRU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential Financial Inc vs Tango Therapeutics Inc. — how do they compare? Prudential Financial Inc trades at $113.5 (market cap $39.13B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Prudential Financial Inc is far larger — about 10.4× Tango Therapeutics Inc.'s market cap, and Prudential Financial Inc pays a 4.94% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 146 Days and Tango Therapeutics Inc. for 0 Days on average.
| PRU | TNGX | |
|---|---|---|
Market Cap | $39.13B | $3.75B |
Volume | 1,369,167 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $125.13 | $32.90 |
52-Week Low | $92.00 | $7.50 |
Typical Hold Time | 146 Days | 0 Days |
Enterprise Value | $67.90B | $2.77B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.49, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but fundamentally attractive valuation metrics including a P/E of 10.28 and P/S of 0.61. Recent earnings show two consecutive quarterly beats, while the company executes strategic initiatives including a $185 million Alexforbes stake sale and rebranding to Prudential Wealth Advisors.
PRU offers value investment appeal with strong profitability metrics (12.46% ROE) and dividend income potential, though facing headwinds from bearish technical trends and mixed analyst sentiment. The company's strategic focus on core businesses and cost reduction provides upside potential, while interest rate sensitivity and competitive pressures remain key monitoring points for investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
